HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Maintains $21 Price Target
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 price target.
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group.
PDS Biotechnology, Pulmonx, Tesla And Some Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 50 points on Tuesday. Here are some big stocks recording losses in today’s session.
HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Raises Price Target to $21
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $15 to $21.
PDS Biotech Reports Median Overall Survival Of 21 Months In Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options With Reported Historical Survival Of 3-4 months
PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced expanded interim data
PDS Biotechnology To Rally Around 129%? Here Are 5 Other Price Target Changes For Tuesday
Chardan Capital raised PDS Biotechnology Corporation (NASDAQ:PDSB) price target from $15 to $16. . Chardan Capital analyst Geulah…
Miniso Group, Monday.com And Other Big Gainers From Monday
U.S. stocks closed lower on Monday, with the Dow Jones dropping more than 200 points. Here is the list of some big stocks recording gains in the previous session.
Dow Surges 150 Points; Crude Oil Falls Sharply
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 150 points on Monday.
PDS Biotech Posts 100% Clinical Response In Cervical Cancer Patients For Its Lead Program
PDS Biotechnology Corporation (NASDAQ:PDSB) announced updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial. The study is investigating PDS0101…
Why PDS Biotechnology Stock Is Soaring Today
PDS Biotechnology Corp (NASDAQ: PDSB) shares are up nearly 30% Monday after the company announced a 100% clinical response in cervical cancer patients in preliminary data from the IMMUNOCERV Phase 2 clinical trial.